二甲双胍的心血管保护作用被引量：1

Cardioprotective effects of metformin

导出

摘要二甲双胍是2型糖尿病的一线治疗药物,在临床应用已有60多年。近年来,二甲双胍的非降糖作用逐渐被发现,其中包括减重、抗肿瘤、抗炎、抗衰老、心脏保护等。与其他降糖药物相比,二甲双胍具有明确的心血管保护作用。该研究将对二甲双胍的心血管保护作用进行系统阐述。 Metformin is a first-line drug in the treatment of type 2 diabetes(T2DM),which has been used clinically for over 60 years.In recent years,metformin's effects beyond glycaemia have been gradually discovered,including weight loss,anti-tumor,anti-inflammatory,anti-aging,and cardioprotection.Compared with other hypoglycemic drugs,metformin has a clear cardioprotective effect.This article will systematically explain the cardioprotective effects of metformin.

作者李金龙牟月晓 Li Jinlong;Mou Yuexiao(Department of Cardiology,the Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong,256600,China;Department of Aesthetic Plastic Medicine,the Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong,256600,China)

机构地区滨州医学院附属医院心血管内科滨州医学院附属医院美容整形医学部

出处《中国基层医药》 CAS 2020年第19期2424-2426,共3页 Chinese Journal of Primary Medicine and Pharmacy

关键词糖尿病 2型心血管系统降糖素类二甲双胍综述 Diabetes mellitus,type 2 Cardiovascular system Hypoglycins Metformin Review

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献1

1张雪扬,杜建玲,贾玉杰,白然,杨郁,巴颖,邢倩,门莉莉.二甲双胍对2型糖尿病患者动脉粥样硬化的一级预防作用[J].中华医学杂志,2009,89(30):2134-2137. 被引量：10

二级参考文献9

1Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 Diabetes. N Engl J Med, 2008, 358: 580-591.
2Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359 : 1577-1589.
3Gaede P, Vedel P, Larsen N, et al. Muhifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348: 383-393.
4Djaberi R, Beishuizen ED, Pereira AM, et al. Non-invasive cardiac imaging teehniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologis,2008, 51 : 1581-1593.
5Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol, 2008, 158 : 631- 641.
6Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res, 2008, 5: 157-167.
7Holman R. Metfomin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu, 2007,13 : 13 -20.
8Manuel LR, Covadonga MA, Francisco AB, et al. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steri, 2009, 91:2527-2536.
9Matsumoto K, Sera Y, Abe Y, et al. Mefformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract, 2004, 64:225-228.